Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Thomas Karasic, MD

Thomas Karasic, MD Physician

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Karasic is employed by Penn Medicine.

Request a Callback
No Patient Satisfaction Reviews
Why not?

There is no publicly available rating for this medical professional for one of the following reasons:

  1. He or she is not employed by Penn Medicine.
  2. He or she does not see patients.
  3. He or she sees patients but has not yet received the minimum 30 patient satisfaction reviews in the past 12 months, ensuring that the rating is statistically reliable and a true reflection of patient satisfaction.
X

Clinical Specialties

Specialty:

  • Hematology
  • Medical Oncology

Programs & Centers:

Board Certification:

  • Internal Medicine, 2015

Clinical Expertise:

  • Anal Cancer
  • Bile Duct Cancer (Cholangiocarcinoma)
  • Colon Cancer
  • Colorectal Cancer
  • Gallbladder Cancer
  • Gastrointestinal Cancer
  • Gastrointestinal Carcinoid Tumor
  • Gastrointestinal Stromal Tumors (GIST)
  • Hepatobiliary Cancer
  • Hepatocellular Carcinoma (HCC)
  • Liver Cancer
  • Liver Tumors
  • Pancreatic Cancer
  • Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)
  • Rectal Cancer
  • Stomach Cancer (Gastric Cancer)

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Columbia University
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania

Memberships

American Association for Cancer Research, National American Society of Clinical Oncology, National American Society of Hematology, National Eastern Cooperative Oncology Group, National

Hospital Affiliation

Dr. Karasic is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Selected Publications:

Karasic TB, O’Hara MH, Loaiza-Bonilla A, Reiss-Binder KA, Teitelbaum UR, Borazanci E, De Jesus-Acosta AC, Redlinger C, Burrell JA, Laheru DA, Von Hoff DD, Amaravadi RK, Drebin JA, O’Dwyer PJ.: Randomized phase II trial of hydroxychloroquine in combination with gemcitabine/nab-paclitaxel to inhibit autophagy in pancreatic cancer: A SU2C-funded trial. American Association for Cancer Research Annual Meeting, Chicago, IL : 2018.

Karasic TB1, Rosen MA2, O'Dwyer PJ3.: Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective? Cancer Chemother Pharmacol. 80 (4): 661-671,2017.

O'Hara MH, Karasic TB, Vasilevskaya I, Redlinger M, Loaiza-Bonilla A, Teitelbaum UR, Giantonio BJ, Damjanov N, Reiss KA, Rosen MA, Heitjan DF, Troxel AB, Amaravadi RK, O'Dwyer PJ.: Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer. American Society of Clinical Oncology Annual Meeting, Chicago, IL : 2017.

Karasic TB, O’Hara MH, Teitelbaum UR, Damjanov N, Giantonio BJ, D’Entremont TS, Gallagher M, Zhang P, O’Dwyer PJ.: Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric Cancer. American Society of Clinical Oncology Annual Meeting, Chicago, IL : 2017.

Karasic T, Loaiza-Bonilla A.: Immunotherapy for hepatobiliary malignancies. GI ASCO 2017 Daily News. : 2017.

Clark AS, Karasic TB, DeMichele A, Vaughn DJ, O'Hara M, Perini R, Zhang P, Lal P, Feldman M, Gallagher M, O'Dwyer PJ.: Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development. JAMA Oncol. 2 (2): 253-60,2016.

Karasic TB, Hei TK, Ivanov VN: Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma. Exp Cell Res 316 (12): 1994-2007,2010.

Ivanov VN, Zhou H, Ghandhi SA, Karasic TB, Yaghoubian B, Amundson SA, Hei TK.: Radiation-induced bystander signaling pathways in human fibroblasts: a role for interleukin-33 in the signal transmission. Cell Signal 22 (7): 1076-87,2010.

Kreindler JL, Bertrand CA, Lee RJ, Karasic T, Aujla S, Pilewski JM, Frizzell RA, Kolls JK.: Interleukin-17A induces bicarbonate secretion in normal human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 296 (2): L257-66,2009.

Academic Contact Info

3400 Civic Center Blvd
PCAM South Tower 12-161

Philadelphia, PA 19104
Phone: (215) 614-1858
Patient appointments: 800-789-7366 (PENN)